While the molecular basis of the action of most anaesthetic agents is unknown, it is a commonly held view that general anaesthetic drugs have a more pronounced effect on synaptic mechanisms in the central nervous system (CNS) than on the propagation of electrical signals along axons [39] . A more contentious issue relates to whether or not anaesthetic agents act generally, producing a range of metabolic alterations which together result in anaesthesia or at, as yet, unidentified specific sites in neuronal mechanisms [25] .
While the molecular basis of the action of most anaesthetic agents is unknown, it is a commonly held view that general anaesthetic drugs have a more pronounced effect on synaptic mechanisms in the central nervous system (CNS) than on the propagation of electrical signals along axons [39] . A more contentious issue relates to whether or not anaesthetic agents act generally, producing a range of metabolic alterations which together result in anaesthesia or at, as yet, unidentified specific sites in neuronal mechanisms [25] .
Sensory information is passed from cell to cell in the CNS by neurotransmitters. These transmitter substances are released in the synaptic cleft between adjacent cells and, depending on the particular synapse, can interact with presynaptic and/or postsynaptic receptors. The postsynaptic actions of transmitter substances are mediated classically via excitatory postsynaptic potentials (EPSP) or inhibitory postsynaptic potentials (IPSP) and the size of these can be modulated by the regulation of transmitter release from the nerve terminal by the interaction of neurotransmitter substances at receptors in the presynaptic membrane.
The diversity of different transmitter substances and the complex interplay between transmitter systems results in a large number of potential sites of action of anaesthetic agents ( fig. 1 ).
EXPERIMENTAL SYSTEMS
Although there have been a number of in vivo studies [4, 9, [55] [56] [57] 65] , by far the majority of studies on the action of anaesthetic agents on transmitter systems have been carried out in in vitro preparations. Three major experimental paradigms, namely synaptosomes, brain slices and cells in culture, have been used in in vitro studies ( fig. 2) . Each of these systems has limitations and caution must be exercised in extrapolating conclusions from these studies to the clinical situation.
Synaptosomes are pinched off nerve endings that are formed when brain tissue is homogenized. The synaptosome fraction is separated from particulate material containing mitochondria and other cell debris by centrifugation in density gradients of either sucrose [27] , Ficoll [11] or Percoll [22] . The resulting synaptosomes are sealed plasma membrane vesicles which contain the secretory machinery and mitochondria necessary for transmitter metabolism and are a good model for the study of the uptake and release of neurotransmitters ( fig. 3 ). The synaptosome preparation consists of a mixed population of nerve endings containing many different transmitter types which permits the study of the metabolism of a number of neurotransmitters in a single system. The major limitations of the synaptosome preparation are that there is the potential for nonphysiological cross-talk between transmitter systems and that the influence of supporting cells and other neurones has been removed by the process of shearing off the nerve endings. For a fuller consideration of the synaptosome preparation see McMahon and Nicholls [40] . Brain slice (pyramid) preparations have also been used extensively to study neurotransmitter metabolism. This is a more complex preparation, as some functional connections are maintained. Possibly the simplest in vitro preparations are neuronal and neuronal-like cells in culture, which permit the study of intact, isolated cell types. Again, the absence of functional tissue organization cannot be ignored and the relevance of observations made on nonneuronal cells, such as chromamn cells, and cells which may be only partially differentiated must be considered.
NEUROTRANSMITTER CLASSIFICATION
Neurotransmitter systems have been subdivided according to their classification into (1) amino acids, (2) other classical transmitters and (3) neuropeptide systems [40] . In this review we concentrate on the group 1 transmitters, including aspartate, glutamate, gamma-aminobutyrate (GABA) and glycine and the group 2 transmitters, including the catecholamines, dopamine, noradrenaline and adrenaline, 5-hydroxytrytamine (5-HT) and acetylcholine, as little work has been directed to the effects of anaesthetic agents on group 3 transmitter systems.
GROUP 1-AMINO ACID TRANSMITTERS
Excitatory transmitters: glutamate and aspartate Glutamate and aspartate are both believed to act as excitatory neurotransmitters in the mammalian brain [24] . In particular, neurotransmission mediated by glutamate has been implicated in learning and memory, neurodegenerative disorders, epilepsy and the effects of hypoxia, ischaemia and possibly other neurological and psychiatric states [16, 20] .
Biosynthesis of glutamate can occur via two pathways, either from the deamination of glutamine or from the tricarboxylic acid cycle [33] (fig. 4) . It would appear that most of the glutamate released following depolarizing stimuli is derived originally from glutamine [33] . After release into the synapse, signal transmission by the excitatory amino acids is mediated at the postsynaptic membrane by receptors for these neurotransmitters. These are classified into three classes, N-methyl-D-aspartate (NMDA), quisqualate and kainate, depending on their pharmacology [69] . The NMD A receptor subclass is of particular importance to the anaesthetist as ketamine is a non-competitive antagonist at this receptor [72] . Postsynaptic events are terminated largely by the uptake of glutamate and aspartate into neighbouring glial cells. In view of their wide distribution and suggested roles in the CNS, the excitatory amino acid transmitter systems constitute an important potential target for anaesthetic action.
Release. In early studies of brain slices, barbiturates were shown to decrease the release of aspartate from electrically stimulated rat lateral olfactory tract slices in a dose-dependent manner [19] . Similarly, depression of potassium-stimulated aspartate release has been observed also in rat brain slices in the presence of pentobarbitone, methohexitone and thiopentone [5, 52, 68] . However, a biphasic pattern of release was observed in a rat thalamic slice preparation in which small concentrations of thiopentone (10~6 mol litre" 1 ) and methohexitone (10~5 mol litre" 1 ) enhanced release and greater doses decreased release of D-aspartate and GABA [37] .
The greater concentration of thiopentone was within the clinical range but that of methohexitone was greater than clinical concentrations. The mechanism of the biphasic response in excitatory amino acid release in response to barbiturates remains unresolved, but may involve indirect effects on GABA transmission [37] . Depolarization-induced calcium uptake in the nerve terminal, which triggers transmitter release, has been shown to be inhibited by thiopentone and pentobarbitone [10] . Hence, alteration in calcium handling by the nerve terminal may provide an explanation for the action of barbiturates on excitatory amino acid transmission.
The steroid anaesthetic hydroxydione is the only other agent which has been shown to inhibit potassium-stimulated aspartate efflux [52] . Other anaesthetic agents, including Althesin (a combination of alphaxalone and alphadolone), ketamine, urethane and halothane have been reported to have no effect or to enhance the release of aspartate from rat brain slice preparations [5, 37, 52] . At clinical doses, 1-2% halothane had no significant effect on the efflux of [ 3 H]aspartate from rat brain slices [5] , although increased aspartate efflux has been observed at larger concentrations of halothane (4-8%) which are considerably greater than the clinical dose range. In contrast, a recent study investigating glutamate release from mice synaptosomes [32] demonstrated an increase in release when the preparation was exposed to clinical concentrations of halothane and enflurane; the increase in release being greater for enflurane than for halothane at equivalent concentrations. Interestingly, the excitatory amino acids are implicated in the pathogenesis of some forms of epilepsy [20] : it is possible that the enhanced release of glutamate in the presence of enflurane could contribute to the electroencephalographic abnormalities seen with this agent [67] .
In vivo measurements of excitatory amino acid release, by monitoring brain concentrations of ascorbate voltammetrically, have shown that anaesthesia with chloral hydrate reduces the release of excitatory neurotransmitters and that transmitter release recovers as the animal recovers [56] . These observations provide in vivo evidence for the interruption of excitatory neurotransmitter release by an anaesthetic agent during the process of anaesthesia.
From the limited evidence available, it is possible that some anaesthetics may act on synaptic transmission mediated by the excitatory amino acids [19, 32, 42, 52, 56, 60] . Perhaps as important, other agents would appear not to be implicated [5, 52] . Together, these results suggest a possible selectivity of action of some anaesthetic agents for the excitatory amino acid release mechanism. The absence of a "general" effect on these transmitter mechanisms is also observed for the volatile agents, as while halothane, and particularly enflurane, increased transmitter release, diethyl ether had no effect in the same study [32] , suggesting selectivity of action of anaesthetic agents on the excitatory transmitter systems.
Recently, a new compound riluzole (54274 RP), has been found to have possible anaesthetic actions and pharmacologically this compound appears to exert its effects by interrupting glutamate neurotransmission [15] . Riluzole has been shown to reduce the presynaptic release of glutamate [15] and also to affect some postsynaptic properties [62] . In one study, riluzole induced loss of righting reflex in rats and in smaller doses it also reduced the MAC of halothane [42] . The inability of riluzole to bind at glutamate receptors [70] suggests that the hypnotic state induced by this agent is different from that produced by ketamine, which is known to be an NMD A receptor antagonist [72] . Interestingly, riluzole protects against glutamate-induced neural injury following ischaemia [41] and this may also provide a further possible use for this novel compound in neurosurgical intensive care. Further investigation of the anaesthetic mechanisms, possibly mediated by altered excitatory amino acid transmission, is certain to follow the initial observations on riluzole action.
Uptake. When glutamate is released from nerve endings, its actions are terminated by uptake into the surrounding glial cells and neurones. In addition, glutamate uptake occurs in the nerve terminal where it is recycled to glutamine [33] . This carrier also transports aspartate into the nerve terminal.
Uptake of aspartate was not affected by thiopentone, methohexitone, ketamine or urethane in a rat brain slice preparation [52] . Similar findings were found in rat thalamic slices using anaesthetic doses of thiopentone, methohexitone, urethane and ketamine [37] . Pentobarbitone, in the same study, did reduce slightly the uptake of aspartate but the authors concluded that this effect was unlikely to contribute to the mechanism of action of the barbiturates.
At present, there is little evidence to link the excitatory amino acid neurotransmitters to anaesthetic mechanisms, despite their possible relevance to consciousness. More work in this area is required to clarify the significance of the anaesthetic effects reported to date [5, 32, 42] .
Inhibitory transmitters : GABA and glycine
GABA. GABA is formed from the irreversible decarboxylation of glutamate, catalysed by the enzyme glutamic acid decarboxylase (GAD) ( fig. 4 ). After release into the synapse, GABA transmission is terminated by uptake of the transmitter by surrounding glial cells and nerve terminals and this process, similar to that for glutamate, limits the activity of GABA in the synapse.
GABA is the major inhibitory neurotransmitter in the central nervous system [33] . By acting on both pre-and postsynaptic receptors, it causes an increase in chloride ion conductance which results in hyperpolarization of the nerve membrane. The barbiturate and steroid anaesthetic agents increase this GABAstimulated chloride conductance, resulting in enhanced hyperpolarization [64] , whereas the volatile anaesthetics have a weaker effect on the GABA receptor-Cl" channel complex [54] .
Catabolism of GABA. In a study using rat brain slices, it was found that 3 % halothane had no effect on either the uptake or release of GABA [14] . However, the catabolism of GABA in the preparation was reduced. This could lead to increased concentrations of GABA in the synapse. Similar effects of halothane on GABA catabolism have also been observed in synaptosomes prepared from rat brain [13] . In addition, clinical concentrations (1 MAC) of chloroform, enflurane and diethyl ether significantly affect GABA catabolism [13] . Of the barbiturates studied, only thiopentone inhibited GABA catabolism at clinical concentrations: pentobarbitone and phenobarbitone had effects only at very large doses [13] . The different actions that have been described, namely reduction in GABA catabolism by the volatile anaesthetic agents and interaction with the GABA receptor-Cl" channel by the barbiturates, illustrate the possibility that different classes of anaesthetic agents may achieve the same physiological effect via different pharmacological mechanisms.
GABA uptake. No effect was found on the uptake of GABA into rat brain slices in the presence of thiopentone, methohexitone, Althesin, ketamine, halothane or urethane [52] . Similarly, pentobarbitone had no effect in rabbit hippocampal slices [34] , or thiopentone, methohexitone, urethane and ketamine in rat thalamic slices [37] . It would appear that the uptake process does not play a significant role in the anaesthetic action of these compounds.
GABA release. Potassium-stimulated GABA release from rat brain slices has been shown to be reduced by the i.v. barbiturates, hydroxydione and pentobarbitone [52] . However, in the rat olfactory cortex preparation, there appeared to be an increase in the release of GABA in the presence of pentobarbitone [19] . In a third study, a biphasic response was observed in the rat thalamus slice preparation, in which small concentrations of thiopentone and methohexitone produced enhanced release, and larger concentrations reduced release [37] . The contrasting effects of barbiturates on GABA release from different brain regions probably reflect the complexity of action of these agents such that it is the balance of the effect on excitatory and inhibitory transmission that results in net excitatory or inhibitory synaptic events. Results obtained from slice preparations may be complicated by secondary cellular cross-talk, and the synaptosome preparation may be more useful for distinguishing primary effects at the level of the GABA releasing terminal.
The conflicting results concerning the effects of anaesthetic agents on the release of GABA from different areas of the brain in vitro [19, 37, 52, 68] , necessitate caution in the extrapolation of observations to the whole animal. In one study, the effect of halothane on the concentration of GABA release in an in vivo preparation was investigated [57] . A microdialysis technique was used in which catheters were placed into the extracellular fluid (ECF) surrounding the brain and the concentrations of neurotransmitters measured. A reduction in GABA content of the ECF was observed in the animals anaesthetized with halothane. Although it was not possible to tell if this reduction was a result of a decrease in release or an increase in uptake, this technique did indicate alteration in transmitter homeostasis in the intact animal.
In summary, the evidence points to a number of potential sites of action of anaesthetic agents on the GABA transmitter system, but as in other transmitter systems, further work is required.
Glycine. Glycine is the major inhibitory neurotransmitter in the spinal cord and medulla and is also implicated widely in other brain regions. This transmitter acts on a receptor-operated chloride channel complex, similar to the GABA receptor-Cl" complex [38] . The effects of anaesthetics on glycine transmission have not been studied extensively, but one study on rat brain slices has indicated that pentobarbitone has no effect on the potassiumstimulated release of glycine [68] . Further study is necessary to investigate the possible role of glycine transmission in anaesthetic mechanisms.
GROUP 2-CATECHOLAMINES, ACETYLCHOLINE AND 5-HT

Nor adrenaline and adrenaline
The characteristics of release of noradrenaline from peripheral nervous tissue have been documented widely, owing to the availability of the chromafnn cell preparation derived from bovine adrenal medullary glands. This cultured cell preparation has been used as a model to investigate the action of anaesthetics on the process of neurosecretion [1, 53, 58, 59] . While contributing to the understanding of anaesthetic mechanisms and, in particular, to their effect on stimulus-secretion coupling, it should be remembered that this is only a model of the mechanisms in the CNS.
The barbiturates, at clinical concentrations, have been shown to reduce both the potassium-and carbachol-stimulated release of noradrenaline from chromafnn cell preparations [58] , and from potassium-stimulated synaptosomes [31] . When the volatile anaesthetic agents halothane ( fig. 5) , enflurane, methoxyflurane and isoflurane were studied, a similar reduction in adrenaline and noradrenaline release was seen when carbachol stimulation was used. However, in contrast to the barbiturates, much larger doses of the volatile anaesthetic agents were needed to inhibit the release after potassiumstimulation. Again, evidence from this experimental system indicates possible selectivity for different classes of anaesthetic agents. However, this apparent selectivity could simply reflect the ability of different anaesthetic agents to reduce calcium concentrations in cells [58, 59] (see below). In contrast to observations on chromaffin cells, reduced potassium-evoked release of noradrenaline has been observed in rat brain slice preparations in the presence of volatile anaesthetic agents at clinical doses ( fig. 6 ) [7, 8] . When applied at equipotent concentrations for producing loss of righting reflex in rats, halothane, enflurane and methoxyflurane were found to reduce potassium-stimulated noradrenaline release by 30 % [7] . It has been suggested that anaesthetic agents may increase the ionic permeability of synaptic vesicles and thereby lead to a decrease in the proton gradients that are essential for synaptic vesicles to accumulate transmitters [6] . This "pump leak" hypothesis has been investigated for noradrenaline in the chromaffin cell system. Halothane, diethyl ether, butanol and ethanol were found to cause only a small insignificant loss of noradrenaline from chromaffin granules [1] , inconsistent with the pump leak hypothesis. By inference, it appears unlikely that depletion of noradrenaline or other neurotransmitters from secretory vesicles could lead to loss of efficiency of synaptic transmission and subsequent anaesthetic state. However, taken together, in vitro observations for noradrenaline and adrenaline release suggest susceptibility of stimulated release mechanisms to modification by anaesthetic agents.
Complimentary studies have been performed in vivo. By manipulation of central noradrenaline concentrations, it has been shown that the MAC of halothane increases with increasing concentrations and decreases with decreasing concentrations, suggesting that reduced noradrenaline transmission may be an important contributory factor to the induction of the anaesthetic state [50] . Thus observations from both in vitro and in vivo investigations indicate that central noradrenaline metabolism is worthy of further study in unravelling the actions of anaesthetic drugs.
Dopamine
Dopamine has a better understood and more localized central action than noradrenaline. As a result, Parkinson's disease and schizophrenia may both be treated using drugs that manipulate central dopamine metabolism. It is noteworthy that amphetamine, which leads to a state of arousal, stimulates dopamine release centrally. By inference, therefore, the dopaminergic system is a potential target for anaesthetic action.
Concentrations of dopamine in the CNS can be manipulated by either increasing concentrations of the dopamine precursor, L-dihydroxyphenylalanine (L-Dopa), to increase concentrations, or by depleting dopamine using l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is an analogue of pethidine that selectively kills central dopaminergic neurones by inhibiting respiratory chain enzymes via a metabolic product. When mice were subjected to these two treatments, L-Dopa decreased the MAC of halothane and MPTP treatment increased the MAC of halothane [65] . Furthermore, when the concentrations of dopamine of MPTP-treated mice were repleted with L-Dopa, the MAC of halothane was restored to control levels.
In a second complex study, using an in vivo microdialysis technique, the effect of halothane anaesthesia on dopamine secretion was investigated [57] . Halothane was found to increase basal concentrations of dopamine when rats were anaesthetized. Results from both these studies conflict with expectations arising from the effects of amphetamine on dopamine metabolism. In vivo and in vitro studies are urgently required to characterize the effects of anaesthetic agents on dopamine metabolism in more detail. In view of the number of patients with alteration in central dopamine pharmacology, an enhanced understanding of anaesthetic mechanisms in the dopaminergic system is likely to have important clinical implications.
5-HT
A precise functional role for 5-HT has yet to be fully established. However, 5-HT has been implicated as an important transmitter in the feeding, sleep, mood, behaviour and cardiovascular control pathways [3] .
5-HT is synthesized from the amino acid Ltryptophan in a two-step pathway. The first, a rate limiting step, involves conversion of L-tryptophan to 5-hydroxytryptophan by the enzyme tryptophan hydroxylase. This is followed by decarboxylation of 5-hydroxytryptophan to 5-HT, catalysed by Laromatic acid decarboxylase. L-tryptophan is transported actively into the nerve terminal and this may be a further limiting factor in the synthesis of 5-HT. After stimulated release into the synapse, the postsynaptic response is terminated by removal of 5-HT from the cleft by a high-affinity active transport mechanism.
To date, only two aspects of 5-HT metabolism have been investigated in the presence of anaesthetic agents, 5-HT uptake and release. There have been no studies on the effects of anaesthetic agents on the uptake of L-tryptophan, or on the rate limiting enzyme tryptophan hydroxylase, which may represent important control points in this transmitter system.
5-HT uptake. In a series of experiments using the rat synaptosome preparation, ketamine, enflurane, halothane and isoflurane [43] [44] [45] 47] inhibited the uptake of 5-HT into the synaptosomal fraction. It is possible that inhibition of uptake may increase the effect of the transmitter at its postsynaptic receptor site as the synaptic activity of 5-HT is terminated by an active re-uptake mechanism. 5-HT is believed to exert its influence on analgesic mechanisms by activating inhibitory mechanisms in the dorsal horn of the spinal cord, hence a decrease in re-uptake may contribute to the anaesthetic effects of these drugs. In contrast, during the same series of experiments, pentobarbitone and etomidate were found to have little effect on the activity of the 5-HT uptake process, again suggesting selectivity for anaesthetic agents on different neuronal activities.
To further investigate the selectivity of action of anaesthetic agents on the 5-HT uptake mechanism, competition binding studies have been carried out using [ 3 H]paroxitene, which binds competitively to the substrate recognition site of the 5-HT transporter [46] . Ketamine caused a concentrationdependent inhibition of specific [ 3 H]paroxetine binding, whereas halothane had no effect. Interestingly, ketamine and halothane were found to induce a similar level of inhibition of 5-HT uptake at clinically relevant concentrations of anaesthetic agents. Thus while ketamine may cause inhibition of 5-HT uptake by direct interaction with the active site of the transport protein, inhibition of uptake by halothane must be mediated, at the very least, by a distinct site on the transporter protein or possibly by mechanisms located elsewhere in the membrane.
Ethanol in sufficient quantities causes general anaesthesia in humans [2] . When an equivalent dose of ethanol was applied in vitro to a synaptosome preparation, the uptake of 5-HT was stimulated [2] , in contrast to other anaesthetic agents studied above [43] [44] [45] [46] [47] . These contrasting effects on the 5-HT transmitter uptake mechanism do not offer a simple explanation for the possible role of this process in anaesthesia.
5-HT release. To date, only the effect of pentobarbitone on 5-HT release from rat midbrain slices has been studied. A small decrease (29 %) in 5-HT release was reported, although this was not significantly different to untreated control samples [68] .
The complex interaction between neurotransmitter systems was well documented in an in vivo study [9] in which a push-pull cannula technique was used to study the influence of acetylcholine on 5-HT release in the cat caudate nucleus. In the control group there was an acetylcholine-dependent re- duction in the release of 5-HT, which was not present in the halothane anaesthetized group. Further experiments suggested that the reduction in 5-HT release observed after application of acetylcholine may be a result of stimulation of GABA interneurones. This work suggests that 5-HT concentrations could vary in response to anaesthetic agents, because of indirect effects on other transmitter systems, and demonstrates the complex interconnections between neurotransmitter systems that are seen in whole animal preparations which cannot be studied easily in in vitro systems.
Acetylcholine
Acetylcholine is well established as an excitatory neurotransmitter. A number of in vivo observations have suggested that cholinergic transmission may be a target for anaesthetic action. In a classical study on acetylcholine transmission, the release of acetylcholine from the surface of the rabbit brain was shown to decrease during barbiturate anaesthesia and increase after a period of feeding and walking, indicating a role for acetylcholine in the maintenance of consciousness [18] . Clinical anaesthetists will be aware also of the prolonged sedative effects that anticholinergic drugs produce, particularly in the elderly population [66] . In a recent study, central cholinergic activity was shown to oppose ketamine anaesthesia [51] and this effect on ketamine anaesthesia was antagonized when the anticholinergic drug 1-hyoscyamine, was given as premedication. These lines of evidence emphasize the important role of acetylcholine in the control of conscious level.
Acetylcholine is synthesized in the nerve terminal from choline and acetyl coenzyme A in a reaction catalysed by choline acetyltransferase (ChAT) (fig.  7) . After release, the acetylcholine signal in the synapse is terminated by hydrolysis by acetylcholinesterase (AChE) and choline is taken up by the presynaptic cell for resynthesis of acetylcholine. The rate limiting step in the synthesis of acetylcholine is probably the uptake of choline into the nerve terminal, making this stage a candidate for the action of anaesthetic agents [36] . Acetylcholine metabolism. The effect of halothane on the uptake of [ 3 H]methylcholine has been investigated in rat brain synaptosomes [28, 35] . A 40% reduction in the uptake of the precursor was demonstrated at halothane concentrations of 2.4 MAC. A similar reduction was seen also when enflurane and isoflurane were studied. Whether the action of the volatile anaesthetics on precursor uptake is competitive [35] or non-competitive [28] has yet to be resolved. As choline uptake is rate limiting [36] for the biosynthesis of acetylcholine, the inhibition of precursor uptake mediated by the volatile anaesthetics may contribute to the state of anaesthesia.
Turnover of acetylcholine in vivo in rat brain regions has been measured under halothane, enflurane and ketamine anaesthesia [55] . The concentrations of acetylcholine and choline in various brain regions did not alter during anaesthesia with any agent. However, halothane decreased the turnover rate for acetylcholine by 10% at 0.7-1.0% inspired concentrations in both cortical and subcortical structures. Interestingly, enflurane did not show any decrease in acetylcholine turnover in subcortical structures and it is possible that this may be associated with the seizure-like activity that develops under enflurane anaesthesia [53] . Unlike halothane and isoflurane which had no effect at 2.4 MAC, enflurane has been shown to alter ChAT activity in rat brain synaptosomes [29] by reducing the Michaelis constant (7-yJ of the enzyme for choline. In vivo, such an effect could potentiate the synthetic pathway for acetylcholine and contribute to the central effects on the electroencephalogram [53] and to the seizure activity that may develop with large inspired concentrations of enflurane. This may also explain the maintenance of acetylcholine concentrations in subcortical structures under enflurane anaesthesia in the in vivo study described above [55] .
Acetylcholine release. Few studies of the effects of anaesthetic agents on release of acetylcholine have been performed. In rat slice preparations, potassiumstimulated acetylcholine release has been shown to be decreased in the presence of pentobarbitone ( fig.  8 ) [60, 61, 68] and methohexitone [61] . Similarly, halothane, at a concentration of 2.5 MAC, has been shown to reduce potassium-stimulated release of acetylcholine by approximately 50%, from a rat brain synaptosome preparation [35] . A reduction in acetylcholine release has also been demonstrated with 1 and 2 % halothane in the cat superior cervical ganglion preparation [12] . However, conflicting results have been obtained in other studies. Halothane, methoxyflurane and enflurane, at concentrations of 1.25 %, 0.2 % and 3 %, respectively, were reported to have no effect on acetylcholine release from a rat brain slice preparation ( fig. 9) [7, 8] and in an isolated cat superior cervical ganglion preparation, chloral hydrate was found to either decrease potassium-stimulated release [61] or to have no effect [48] .
In the above studies, total acetylcholine release was measured in synaptosomes [35] , while release of [ 3 H]acetylcholine was monitored in the brain slice studies [7, 8] . Differential labelling of intracellular pools of acetylcholine in the nerve terminal [71] could underlie some of the differences in the observations [7, 8, 35] . In addition, rat brain slices are known to be more sensitive to potassium depolarization than synaptosomes [63] and this could also account for differences in actions of anaesthetics between the preparations. Comparisons between these studies may be further complicated by the different doses of anaesthetic agents applied in the various studies [8, 35] .
OTHER TRANSMITTERS A number of other transmitter systems, in particular those classified as group 3, including neuropeptides such as substance P, the opioids and thyrotrophin releasing hormone (TRH), have received little or no attention with respect to the effects of anaesthetics. At present, 40 neuroactive peptides have been identified, but not all satisfy the criteria for neurotransmitters [38] . Therefore there remains a large amount of work before questions regarding selectivity of anaesthetic action can be answered fully.
THE ROLE OF CALCIUM IN NEUROTRANSMITTER RELEASE: EFFECT OF ANAESTHETIC DRUGS
Influx of extracellular calcium is essential for the coupling of electrical excitation to neurotransmitter release [17] . Two phases of depolarization-induced calcium entry into the nerve terminal have been characterized, a rapid phase and a slower plateau phase [40] . The release of different neurotransmitters may rely on different phases of the calcium current [40] . As calcium is crucial to neurotransmitter release, this aspect of stimulus-secretion coupling may be a potential site of action of anaesthetic agents and may present a mechanism by which some selectivity of anaesthetic action may occur. Depolarization-induced calcium uptake into synaptosomes has been shown to be reduced in the presence of a wide range of anaesthetic agents [10, 21, 30] . Furthermore, in bovine chromaffin cells, anaesthetic-induced reduction in calcium influx has been linked to a decrease in evoked noradrenaline release in the presence of pentobarbitone, halo thane ( fig. 10) , isoflurane, enflurane and methoxyflurane [58, 59, 73] . When noradrenaline release from chromaffin cells was stimulated with carbachol or potassium, carbachol-evoked release appeared to be more susceptible to the action (reproduced with permission from [73] ).
of clinical doses of volatile anaesthetic agents than potassium-evoked release. Inhibition of potassiumstimulated release was affected only at supraclinical doses of anaesthetic agents. These results are most likely to be explained by the concentration of calcium in the cell achieved after the two stimulation procedures. When stimulated with potassium, the influx of calcium was much greater than when stimulation was with carbachol, thus halothaneinduced reduction in intracellular calcium concentrations to threshold concentrations for transmitter release was more easily achieved under carbachol stimulation. These results are consistent with an important role for calcium homeostasis in anaesthetic-induced modulation of neurotransmitter release.
The possibility that reductions in calcium influx in the presence of anaesthetic agents may be linked to the membrane disordering properties of these drugs has been investigated further [21, 30] . No simple relationship between the ability of anaesthetic agents to reduce calcium influx and disorder membrane structure was shown. A stronger correlation was found between the effect on sodium influx and membrane perturbation [30] .
DIRECT VERSUS INDIRECT ACTIONS OF ANAESTHETIC AGENTS ON PRESYNAPTIC TRANSMITTER MECHANISMS
So far in this discussion, consideration of anaesthetic effects at the level of the presynapse has focused on specific aspects of synaptic transmission mediated by a variety of transmitter agents. A variety of effects have been reported, some of which may be compatible with the onset of anaesthesia. An important question that remains is how the anaesthetic agents exert their effects on such a range of biochemical systems.
From a pharmacological perspective, most general anaesthetic agents would appear to be essentially non-specific in their actions at the level of transmitter metabolism and release. However, as can be seen from the above discussion, not all anaesthetics produce the same response in the assay systems exploited, indicating some degree of selectivity of action (see tables I and II). Indeed, it is possible that certain anaesthetic agents are found to exert their primary effects in a specific manner at the level of discrete proteinaceous acceptors, for example ketamine acts at the NMD A receptor [51] and at the active site of the 5-HT transporter [46] , the barbiturates act at the GABA receptor-Cl~ complex [65] and isoflurane produces stereoselective activation of a potassium channel subtype [26] . However, when agents such as the volatile anaesthetic agents are considered, a wide spectrum of effects in different transmitter systems is observed, involving not only presynaptic but also postsynaptic events. In these cases, anaesthetic effects may reflect the susceptibility of discrete cellular functions to non-specific, anaesthetic-mediated changes in the local environment rather than specific interactions with proteinaceous acceptors. Hence, anaesthesia may be the net result of a combination of a large number of nonspecific toxicological effects on CNS function that [19]|, [52] ;, [68] ; [60] , [61] , [68] ;
[6i];
[31], [58] ;, [68] ;
any particular agent exerts. If so, the "physiological mechanism" of anaesthesia may well be different for each agent. At the present time, there have been insufficient studies to allow any definitive statements to be made concerning the relevance of the action of anaesthetic agents on presynaptic transmitter release mechanisms to the overall mechanisms of general anaesthesia (see tables I and II). In many cases, our knowledge of the effects of anaesthetic agents on discrete presynaptic activities depends on one or two studies. Often these have been carried out on more than one experimental system and under different experimental conditions, such that a true comparison of results is not possible. More systematic studies of the actions of general anaesthetic agents on individual presynaptic activities in defined experimental systems and under comparable conditions are urgently required. Furthermore, these should include both in vitro and in vivo studies to allow primary and secondary effects of anaesthetic agents to be dissected. While in vitro studies may allow effects on specific functions to be studied more easily, the importance of in vivo studies must be stressed to permit the discrimination of statistically significant changes measured in vitro which have no physiological relevance in vivo. Since a universal action of general anaesthetic agents cannot be ruled out, one aim of these studies should be to identify central activities that are universally altered by general anaesthetic agents in a manner consistent with the induction of the anaesthetic state. The likelihood is, however, that physiological mechanisms of anaesthesia will prove to be much more complex.
The feature that unifies all general anaesthetic agents is their relatively high hydrophobicity. Indeed, lipid solubility is the only property of all anaesthetic agents that appears to correlate with anaesthetic potency [49] . Hence, anaesthesia may depend solely on the ability of any agent to disrupt local hydrophobic environments such that central mechanisms in the control of consciousness become disrupted. Selectivity of agents may, therefore, be related to their ability to penetrate hydrophobic domains of different central functional structures [23] . It is likely that many of the effects of anaesthetic drugs will be mediated via their disordering effects in the lipid bilayer of the cell membrane [49] . Where anaesthetic effects on membrane functions are shown, it will be important to investigate the possible relationship of these changes with alterations in the membrane environment.
When individual central activities are considered, the anaesthetic agents appear not to act in concert but to exert some selectivity. For example, the barbiturates exert different effects on excitatory amino acid transmitter release than the volatile anaesthetics [5, 19, 32, 37, 52] . Further study of presynaptic transmitter systems may allow agents to be grouped functionally which, in turn, may simplify the investigation of their mechanisms.
